ClinicalTrials.gg
CompletedNCT02680041LOCATEUpdated Jan 28, 2019Results posted

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

A Phase 3 interventional study of 18F-fluciclovine PET CT in Prostate Cancer, sponsored by Blue Earth Diagnostics. Completed at 17 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-28.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
221
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing fluciclovine F-18 in Prostatic Neoplasms — 2 open to participants now, 3 under way, none of them phase 3. fluciclovine F-18 · Prostatic Neoplasms.

Enrollment
Largest of 14
221 · median 28
Started
2016
the only one that year
Phase 3
Only one
of the 14
Registered
6th of 14
by date
Lead sponsor
2 of 14
Blue Earth Diagnostics

Among the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, this one has the largest enrollment, is the only one that started in 2016, is the only one in phase 3, and was the 6th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About fluciclovine F-18

fluciclovine F-18: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This prospective study will enroll up to 330 men with PSA-persistent or PSA-recurrent prostate cancer after curative-intent primary therapy and negative or equivocal findings on standard-of-care imaging. Consenting participants will be imaged with 18F-fluciclovine PET/CT. Site clinicians will manage study subjects per standard practices and will document any change in treatment based on review of 18F-fluciclovine PET/CT findings. All participants will be followed for up to 6 months, with clinical data collected for this study. An interdisciplinary panel will provide expert guidance to local readers on request. The final reporting of the PET/CT scan will be a single report by the local reader following any such discussion.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).
  • Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :
  • Post prostatectomy: Detectable or rising PSA level that is >0.2 ng/mL with a second confirmatory level of >0.2 ng/mL
  • Post non-prostatectomy: PSA rise ≥ 2ng/mL over nadir
  • Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).
  • Being considered for salvage therapy
  • Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.
  • Previous brachytherapy treatment will have occurred at least 2 years in the past
  • Ability to understand and the willingness to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)
  • Androgen deprivation therapy (ADT) in the past 3 months
  • History of bilateral orchidectomy
  • Inability to tolerate 18F-fluciclovine PET/CT
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    18F-fluciclovine PET CT

    Single intravenous administration of 18F-fluciclovine PET CT.

    Drug: 18F-fluciclovine PET CT

Interventions

  • Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment

    Also known as: FACBC

06

What researchers measure

Primary outcomes

  1. The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease.

    The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT

    Time frame: 2-22 days post PET CT

Secondary outcomes

  1. The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Actual Treatment

    The change of management will be based on referring physician questionnaires completed pre- 18F-fluciclovine PET/CT and changes reported at 6 month follow-up. Investigators were instructed to assess any clinically significant change from the revised management plan.

    Time frame: 6 months

  2. The Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population

    The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT

    Time frame: 1 week

  3. The Rate of Detection of Disease in 1) Prostate and Prostate Bed and 2) Extra-prostatic Regions With 18F-fluciclovine PET/CT in the Study Population

    The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally

    Time frame: 1 week

  4. The Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy

    Based on the ratio of positive findings in the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI

    Time frame: 6 months

  5. The PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy

    Based on the ratio of positive findings outside the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI

    Time frame: 6 months

07

Results

Posted Jan 28, 2019

Participant flow

The study was conducted between 01 June 2016 (first patient, screening visit) and 01 November 2017 (last patient, last contact) at 17 sites in the USA. Overall 17 sites were initiated, of which 15 sites enrolled patients.

Participant flow — Overall Study
Milestone18F-fluciclovine PET CT
Started221
Received 18f-fluciclovine213
Completed211
Not completed10
Withdrew: Withdrawal prior to 18f-fluciclovine pet8
Withdrew: Lost to follow-up2

Outcome measures

PrimaryThe Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease.

The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT

Time frame:
2-22 days post PET CT
Reported as:
Count of participants · Participants
The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Planned Treatment Through Detection of Disease.
Participants18F-fluciclovine PET CT
Overall Evaluable Analysis Set — Patients with Revised Management Plan126
Overall Evaluable Analysis Set — No Revision to Management Plan87
Positive 18F-fluciclovine Scan — Patients with Revised Management Plan88
Positive 18F-fluciclovine Scan — No Revision to Management Plan34
Negative 18F-fluciclovine Scan — Patients with Revised Management Plan38
Negative 18F-fluciclovine Scan — No Revision to Management Plan53
SecondaryThe Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Actual Treatment

The change of management will be based on referring physician questionnaires completed pre- 18F-fluciclovine PET/CT and changes reported at 6 month follow-up. Investigators were instructed to assess any clinically significant change from the revised management plan.

Time frame:
6 months
Reported as:
Count of participants · Participants
The Fraction of Patients for Whom 18F-fluciclovine PET/CT Alters Patient Actual Treatment
Participants18F-fluciclovine PET CT
Overall — Change from the revised management plan80
Overall — No change from the revised management plan131
Positive 18F fluciclovine Scan — Change from the revised management plan47
Positive 18F fluciclovine Scan — No change from the revised management plan74
Negative 18F fluciclovine Scan — Change from the revised management plan33
Negative 18F fluciclovine Scan — No change from the revised management plan57
SecondaryThe Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population

The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT

Time frame:
1 week
Reported as:
Count of participants · Participants
The Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population
Participants18F-fluciclovine PET CT
The Rate of Detection of Any Disease Site by 18F-fluciclovine PET/CT in the Study Population122
SecondaryThe Rate of Detection of Disease in 1) Prostate and Prostate Bed and 2) Extra-prostatic Regions With 18F-fluciclovine PET/CT in the Study Population

The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally

Time frame:
1 week
Reported as:
Count of participants · Participants
The Rate of Detection of Disease in 1) Prostate and Prostate Bed and 2) Extra-prostatic Regions With 18F-fluciclovine PET/CT in the Study Population
Participants18F-fluciclovine PET CT
Prostate or Prostate Bed64
Extra-prostatic80
SecondaryThe Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy

Based on the ratio of positive findings in the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI

Time frame:
6 months
Reported as:
Number · Percentage of scans
The Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy
Percentage of scans18F-fluciclovine PET CT
The Positive Predictive Value (PPV) of 18F-fluciclovine PET/CT for Regional Disease Compared to Biopsy in Those Patients Who Undergo Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy100 (92.1 to 100.0)
SecondaryThe PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy

Based on the ratio of positive findings outside the pelvis on 18F-fluciclovine PET/CT which are confirmed by histological examination of tissue or MRI

Time frame:
6 months
Reported as:
Number · Percentage of scans
The PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy
Percentage of scans18F-fluciclovine PET CT
The PPV of 18F-fluciclovine PET/CT for Distant Disease Compared to Biopsy in Those Patients Who Undergo a Biopsy or in Case of Bony Disease a Correlation With MRI or Biopsy100 (90.5 to 100.0)

Adverse events

Collected over As specified in the Statistical Analysis Plan, results are presented as only those treatment-emergent adverse events which occurred up to 42 days after the 18F fluciclovine administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
18F-fluciclovine PET CT0/213 (0%)0/213 (0%)44/213 (20.7%)
Most frequent other events
Showing 10 of 57
Most frequent other events
Event18F-fluciclovine PET CT
DiarrhoeaGastrointestinal disorders6/213
HeadacheNervous system disorders6/213
ConstipationGastrointestinal disorders2/213
HaematuriaRenal and urinary disorders2/213
NocturiaRenal and urinary disorders2/213
PollakiuriaRenal and urinary disorders2/213
Urinary IncontinenceRenal and urinary disorders2/213
Oedema peripheralGeneral disorders2/213
AnxietyPsychiatric disorders2/213
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/213

Baseline characteristics

Full Analysis Set

Age, Continuous
Age, Continuous(years)18F-fluciclovine PET CT
Median67.0 (46 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)18F-fluciclovine PET CT
Female0
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)18F-fluciclovine PET CT
Hispanic or Latino9
Not Hispanic or Latino202
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)18F-fluciclovine PET CT
American Indian or Alaska Native1
Asian3
Native Hawaiian or Other Pacific Islander2
Black or African American17
White188
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)18F-fluciclovine PET CT
United States213
08

Study locations

17 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Tower Urology
    Los Angeles, California 90048, United States
  • Genesis Research, LLC
    San Diego, California 92123, United States
  • University of Florida
    Jacksonville, Florida 32209, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Roudebush VA Medical Center
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Coastal Urology Associates
    Brick, New Jersey 08724, United States
  • Manhattan Medical Research
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Urologic Consultants of SE Pennsylvania
    Bala-Cynwyd, Pennsylvania 19004, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
09

References and documents

Publications

  • Savir-Baruch B, Lovrec P, Solanki AA, Adams WH, Yonover PM, Gupta G, Schuster DM. Fluorine-18-Labeled Fluciclovine PET/CT in Clinical Practice: Factors Affecting the Rate of Detection of Recurrent Prostate Cancer. AJR Am J Roentgenol. 2019 Oct;213(4):851-858. doi: 10.2214/AJR.19.21153. Epub 2019 Jun 19. PubMed 31216198 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Nov 2017, 17 months.

Results were first posted in Jan 2019, 1 year 2 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 17 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2016
First posted
Feb 11, 2016
StartActual
Jun 1, 2016
Primary completionActual
Nov 1, 2017
CompletionActual
Nov 1, 2017
Results first posted
Jan 28, 2019
Last update
Jan 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02680041
Collaborators
American College of Radiology, IND 2 Results LLC, Syne Qua Non Limited
Responsible party
Sponsor
First posted
Feb 11, 2016
Start date
Jun 1, 2016
Primary completion
Nov 1, 2017
Completion
Nov 1, 2017
Results posted
Jan 28, 2019
Last update
Jan 28, 2019

Study contacts

Umar Mahmood, MD, PhD
study chair · Harvard Medical School (HMS and HSDM)
Peter Gardiner, MB ChB, MRCP, FFPM
study director · Blue Earth Diagnostics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluciclovine F-18

Start the discussion